COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD
In accordance with currently accepted recommendations for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), both monotherapy with long-acting anticholinergics (LAAC) or combined therapy (LAAC / long-acting beta-agonists, LABA) can be used. To justify a rational choice betw...
Saved in:
| Main Authors: | E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2017-08-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/197 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01) -
Current views on the use of long-acting anticholinergic drug tiotropium in the treatment of bronchial asthma among children
by: E. V. Churyukina
Published: (2023-03-01) -
Dynamics of somatogenic comorbid anxiety-depressive disorders expression under the tiotropium bromide treatment influence
by: S. V. Fedosenko, et al.
Published: (2011-02-01) -
Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation
by: S. К. Zyryanov, et al.
Published: (2022-07-01) -
PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: A. U. Kulikov, et al.
Published: (2015-03-01)